Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7947402 | 0.94 | EDNRA (0.89) | EDNRAEDNRB | |
| SCHEMBL5247182 | 0.93 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL7343101 | 0.93 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL4630737 | 0.93 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL5210621 | 0.92 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL5210083 | 0.92 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL2770488 | 0.91 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL30037067 | 0.91 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL4631836 | 0.91 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL4631845 | 0.91 | EDNRA (0.83) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1498418-B1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-05-21 | — | — | EP | claimed |
| EP-0980369-B1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | claimed |
| EP-1498418-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | claimed |
| US-6683103-B2 | SULFONAMIDES CONTAINING OXAZOLE AND SUBSTITUTED THIOPHENE RINGS, USEFUL FOR TREATING HYPERTENSION, CARDIOVASCULAR DISEASE, ASTHMA, PULMONARY HYPERTENSION, INFLAMMATORY DISEASES, VISION DEFECTS, MENSTRUAL DISORDERS, RENAL FAILURE | TEXAS BIOTECHNOLOGY CORPORATION | 2004-01-27 | — | — | US | claimed |
| US-6432994-B1 | CARDIOVASCULAR DISORDERS, GLAUCOMA; ANTIINFLAMMATORY, WOUND HEALING, HYPOTENSIVE, ANTIASTHMATIC, AND ANTIANAPHYLACTIC AGENTS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-08-13 | — | — | US | claimed |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | claimed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | claimed |
| EP-0980369-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998049162-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-11-05 | — | — | WO | claimed |
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | REMD BIOTHERAPEUTICS INC (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250339445-A1 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | UNIV EMORY (US) | 2025-11-06 | — | — | US | disclosed |
| CN-111405899-B | Combination of 4-pyrimidine sulfonamide derivatives with SGLT-2 inhibitors for the treatment of endothelin related disorders | 爱杜西亚药品有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20250120973-A1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-04-17 | — | — | US | disclosed |
| EP-3716979-B1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-6683103-B2 | SULFONAMIDES CONTAINING OXAZOLE AND SUBSTITUTED THIOPHENE RINGS, USEFUL FOR TREATING HYPERTENSION, CARDIOVASCULAR DISEASE, ASTHMA, PULMONARY HYPERTENSION, INFLAMMATORY DISEASES, VISION DEFECTS, MENSTRUAL DISORDERS, RENAL FAILURE | TEXAS BIOTECHNOLOGY CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6432994-B1 | CARDIOVASCULAR DISORDERS, GLAUCOMA; ANTIINFLAMMATORY, WOUND HEALING, HYPOTENSIVE, ANTIASTHMATIC, AND ANTIANAPHYLACTIC AGENTS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-0980369-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998049162-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | EDNRA, ECE1, EDNRB | EDNRA 1/4885EDNRB 3/4885 |
| US-20250339445-A1 | Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke | RXRA, RXRG, RXRB | EDNRA 709/4885EDNRB 993/4885 |
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | EDNRA, EDNRB, FCGR2A | EDNRA 1/4885EDNRB 2/4885 |
| US-20250120973-A1 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | SLC5A2, SLC5A1, GLP1R | EDNRA 6/4885EDNRB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.